The goal of this clinical trial is to learn if neuromodulation of the dorsal genital nerve works to treat symptoms related to Persistent Genital Arousal Disorder in women. The main questions it aims to answer are: What is the effect of neuromodulation on PGAD symptoms in women? Participants will: Use a neurosimulator every day for 3 weeks. Keep a diary of their symptoms and the number of times they used the neurostimulator Fill in questionaires
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Neuromodulation by UCon
Radboud Unversity Medical Center
Nijmegen, Netherlands
Symptom severity
Symptom severity on a 5-point Likert scale, filled in daily. 1 indicates no symptoms at all, 5 indicates very severe symptoms.
Time frame: 8 weeks
Neuromodulation effect
The neuromodulation effect will be assessed using a self-reported diary, where participants are prompted daily to rate their experience of symptoms in response to the question: "How do you experience your symptoms today?" Responses are recorded on a 5-point Likert scale with the following options: "No problem," "Mild," "Moderate," "Severe," or "Very severe." This dairy is quaried during the three weeks intervention period, in which the participants use the neuromodulator device daily.
Time frame: 3 weeks
Satisfaction device
The consideration of using the neuromodulator device as part of their treatment, which was asked at the end of the treatment with the question "Would you like to continue using the device as part of your treatment". Following with a 'Yes' or 'No' answer.
Time frame: At the end of the treatment, at week 8
HADS
Hospital Anxiety and Depression Scale, measuring the level of anxiety and depression, both scores ranging from 0 to 21: 0-7 : no anxiety disorder or depression 8-10 : possible anxiety disorder or depression 11-21: suspected anxiety disorder or depression
Time frame: At baseline, at the end of the intervention (week 3) and at the end of post-intervention (week 8)
PCS
Pain Catestrophizing Scale. Score ranging from 0 to 52, in which a higher score indicates a higher level of pain catestrophizing.
Time frame: At baseline, at the end of the intervention (week 3) and at the end of post-intervention (week 8)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
QoL
Quality of Life measured with the EQ-5D-3L (EuroQol-5 Dimensions-3 Levels). The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. Higher EQ VAS score indicated higher self-related health.
Time frame: At baseline, at the end of the intervention (week 3) and at the end of post-intervention (week 8)
Patient Global Impression of Improvement
Patient Global Impression of Improvement (PGI-I) is a scale to rate the patients condition now, as compared with how it was prior to before beginning treatment on a scale from 1. Very much better to 7. Very much worse.
Time frame: During follow-up (after week 8)